Investigating the Cytotoxic and Apoptotic Effects of Telmisartan, both independently and in combination with Doxorubicin, on a Lung Cancer Cell Line
DOI:
https://doi.org/10.36320/ajb/v17.i1.19051Keywords:
Telmisartan, Anticancer, Lung cancer, BCL-2, ApoptosisAbstract
Telmisartan (Tel), an angiotensin receptor blocker, has shown potential in enhancing the anticancer efficacy of Doxorubicin (Dox) against lung cancer, a leading cause of global mortality. This study investigated the cytotoxic and apoptotic effects of Tel alone and in combination with Dox on A549 lung cancer cells. Cells were divided into four groups (control, Tel-treated, Dox-treated, and Tel + Dox-treated) and exposed to six drug concentrations. After 72 hours, cytotoxicity and IC50 values were assessed, followed by BCL-2 expression analysis and apoptosis quantification. Results showed that Tel alone had modest cytotoxicity, but its combination with Dox significantly enhanced anticancer activity, achieving 86.78% cytotoxicity at 800 µg/ml. The combination therapy reduced Dox’s IC50 from 292.46 µg/ml to 72.21 µg/ml (CI = 0.45), indicating strong synergy. The dose reduction index revealed a significant decrease in the required Dox dosage when combined with Tel. Furthermore, Tel treatment significantly reduced BCL-2 expression (P < 0.0458) compared to the control, similar to the reduction observed in Dox-treated cells. Apoptosis analysis demonstrated a higher percentage of apoptotic cells in Tel-treated groups compared to controls, with Dox inducing slightly greater apoptosis than Tel, though not statistically significant. These findings suggest that Telmisartan enhances Doxorubicin's anticancer effects by inducing apoptosis through a BCL-2-dependent mechanism, highlighting its potential as a combinational therapeutic strategy for lung cancer treatment.
Downloads
References
1. Zhou, C., Qin, Y., Zhao, W., Liang, Z., Li, M., Liu, D., Bai, L., Chen, Y., Chen, Y. & Cheng, Y. 2023. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease. Translational Lung Cancer Research, 12, 1661.
2. EMRO, W. 2009. Towards a strategy for cancer control in the Eastern Mediterranean Region.
3. AL HASNAWI, S. M., AL MOSAWI, A. J., YONAN, O. F., FADHIL, H. M. & SAMI, S. 2009. The Histopathological pattern of lung cancer in Iraq. New Iraqi Journal of Medicine [The], 5, 80-83.
4. Travis, W.D. (2020) ‘Lung cancer pathology: current concepts,’ Clinics in chest medicine, 41(1), pp. 67–85.
5. Yang, C.-Y., Yang, J. C.-H., & Yang, P.-C. (2020). Precision management of advanced non–small cell lung cancer. Annual Review of Medicine, 71(1), 117– 136.
6. Cheng, Z. et al. (2021) ‘Nanomaterials for cancer therapy: Current progress and perspectives,’ Journal of Hematology & Oncology, 14(1), pp. 1–27.
7. Ashrafi, Adnin, et al. "Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance." Cancers 14.19 (2022): 4562.
8. KCIUK, M., GIELECIŃSKA, A., MUJWAR, S., KOŁAT, D., KAŁUZIŃSKA-KOŁAT, Ż., CELIK, I. & KONTEK, R. 2023. Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells, 12, 659.
9. Xie, S., Sun, Y., Zhao, X., Xiao, Y., Zhou, F., Lin, L., Wang, W., Lin, B., Wang, Z. & Fang, Z. 2024. An Update of the Molecular Mechanisms underlying anthracycline induced cardiotoxicity. Frontiers in Pharmacology, 15, 1406247. https://doi.org/10.3389/fphar.2024.1406247.
10. chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, Dong X. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 2012.
11. Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y, Narahara H. Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS One. 2014
12. Okazaki M Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T, Ohta T. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. Cancer Lett. 2014.
13. Pinter, Matthias Jain,2017, Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.
14. Cheng, Z. et al. (2021) ‘Nanomaterials for cancer therapy: Current progress and perspectives,’ Journal of Hematology & Oncology, 14(1), pp. 1–27.
15. AROZAL,W.,WATANABE, K., VEERAVEEDU, P. T., THANDAVARAYAN, R. A., HARIMA, M., SUKUMARAN, V., SUZUKI, K., KODAMA, M. & AIZAWA, Y. 2010. Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. Journal of Pharmacy and Pharmacology,62,1776-1783 .
16. Sohail, A., Hasnain, M. M., Haq, M. E. U., Nasir, I., Sufyan, R., Khan, M. & Ullah, I. 2024. Oxidative Stress and Antioxidant Interventions in Type 2 Diabetes.
17. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK general practice research database. BMJ. 2012.
18. Makar GA, Holmes JH, Yang YX. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst. 2014.
19. Giard, D.J. et al. (1973) ‘In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid Tumors2’, JNCI: Journal of the National Cancer Institute, 51(5), pp. 1417–1423. Available at: https://doi.org/10.1093/jnci/51.5.1417.
20. Ji, H. (2010) ‘Lysis of Cultured Cells for Immunoprecipitation,’ Cold Spring Harbor Protocols, 2010(8), p. pdb.prot5466. Available at: https://doi.org/10.1101/pdb.prot5466.
21. Sulaiman GM, Waheeb HM, Jabir MS, Khazaal SH, Dewir YH, Naidoo Y. Hesperidin Loaded on Gold Nanoparticles as a Drug Delivery System for a Successful Biocompatible, Anti-Cancer, Anti-Inflammatory and Phagocytosis Inducer Model. Sci Rep [Internet]. 2020;10(1):9362. Available from: https://doi.org/10.1038/s41598-020-66419-6
22. Helmy IM, Abdel Azim AM. Efficacy of ImageJ in the assessment of apoptosis. Diagn Pathol [Internet]. 2012;7(1):15. Available from: https://doi.org/10.1186/1746-1596-7-15
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ali Imad Hameed, Shaymaa F. Abbas, Jawad K. Hasan
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
